ReShape Lifesciences Inc. (RSLS)
NASDAQ$0.63
Market Cap
$2.08M
Sector
Healthcare
Industry
Medical—Devices
Rank in Sector
820 of 924
Rank in Industry
103 of 118
Insider Buys Sum
Cluster
Trading
Trading
Insider Buys
Quantity
Quantity
Historical
Profitability
Profitability
Investor
Ownership
Ownership
Largest Insider Buys in Sector
RSLS Insider Trading Activity
RSLS Median Price and Trade Amounts History Chart
Statistics of Insider Transactions
Amount of Insider Buys and Sells
Buys | $0 | 0 | 0 |
Sells | $12 | 1 | 100 |
Related Transactions
| STANKOVICH THOMAS | Chief Financial Officer | 0 | $0 | 1 | $12 | $-12 |
About ReShape Lifesciences Inc.
ReShape Lifesciences Inc., a medical device company, provides products and services that manages and treat obesity and metabolic diseases in the United States, Australia, Europe, and internationally. The company's product portfolio includes Lap-Band System, a minimally invasive long-term treatment of severe obesity and more invasive surgical stapling procedures, such as the gastric bypass or sleeve gastrectomy; and ReShape Vest system, an investigational, minimally invasive, laparoscopically implanted medical device that wraps around the …
Insider Activity of ReShape Lifesciences Inc.
Over the last 12 months, insiders at ReShape Lifesciences Inc. have bought $0 and sold $12 worth of ReShape Lifesciences Inc. stock.
On average, over the past 5 years, insiders at ReShape Lifesciences Inc. have bought $54,613 and sold $4.03M worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 17,702 shares for transaction amount of $26,907 was made by STANKOVICH THOMAS (Chief Financial Officer) on 2023‑06‑30.
List of Insider Buy and Sell Transactions, ReShape Lifesciences Inc.
| 2024-05-31 | Sale | STANKOVICH THOMAS | Chief Financial Officer | 48 0.0002% | $0.25 | $12 | -61.77% | |
| 2024-02-29 | Sale | STANKOVICH THOMAS | Chief Financial Officer | 43 0.0002% | $0.17 | $7 | -3.89% | |
| 2023-12-31 | Sale | STANKOVICH THOMAS | Chief Financial Officer | 42 0.0003% | $0.25 | $11 | -31.72% | |
| 2023-11-30 | Sale | STANKOVICH THOMAS | Chief Financial Officer | 39 0.0003% | $0.23 | $9 | -23.73% | |
| 2023-10-25 | Sale | STANKOVICH THOMAS | Chief Financial Officer | 131 0.0027% | $0.27 | $35 | -26.31% | |
| 2023-10-11 | Sale | STANKOVICH THOMAS | Chief Financial Officer | 39 0.0026% | $0.93 | $36 | -28.83% | |
| 2023-09-01 | Sale | STANKOVICH THOMAS | Chief Financial Officer | 118 0.0034% | $0.89 | $105 | -77.60% | |
| 2023-08-24 | Sale | STANKOVICH THOMAS | Chief Financial Officer | 39 0.0013% | $1.42 | $55 | -82.09% | |
| 2023-08-04 | Sale | STANKOVICH THOMAS | Chief Financial Officer | 108 0.0036% | $1.43 | $154 | -84.79% | |
| 2023-07-06 | Sale | STANKOVICH THOMAS | Chief Financial Officer | 106 0.0064% | $1.47 | $156 | -83.66% | |
| 2023-06-30 | STANKOVICH THOMAS | Chief Financial Officer | 17,702 1.0643% | $1.52 | $26,907 | -84.10% | ||
| 2023-05-31 | Sale | STANKOVICH THOMAS | Chief Financial Officer | 98 0.0057% | $2.41 | $236 | -89.68% | |
| 2023-04-30 | Sale | STANKOVICH THOMAS | Chief Financial Officer | 96 <0.0001% | $2.36 | $227 | -64.13% | |
| 2023-03-31 | Sale | STANKOVICH THOMAS | Chief Financial Officer | 109 <0.0001% | $2.60 | $283 | -85.04% | |
| 2023-02-28 | Sale | STANKOVICH THOMAS | Chief Financial Officer | 103 <0.0001% | $4.25 | $438 | -76.97% | |
| 2023-02-02 | Sale | STANKOVICH THOMAS | Chief Financial Officer | 157 <0.0001% | $13.29 | $2,087 | -78.25% | |
| 2023-01-24 | Sale | STANKOVICH THOMAS | Chief Financial Officer | 158 <0.0001% | $7.49 | $1,183 | -81.24% | |
| 2022-12-01 | Sale | STANKOVICH THOMAS | Chief Financial Officer | 7,357 0.0335% | $0.15 | $1,112 | -69.71% | |
| 2022-11-28 | Sale | STANKOVICH THOMAS | Chief Financial Officer | 364,756 1.9555% | $0.17 | $61,826 | -68.05% | |
| 2022-11-04 | Sale | STANKOVICH THOMAS | Chief Financial Officer | 8,393 0.0385% | $0.27 | $2,287 | -82.14% |
Total: 100
*Gray background shows transactions not older than one year
Insider Historical Profitability
34.16%
| STANKOVICH THOMAS | Chief Financial Officer | 22777 0.6891% | $14,349.51 | 6 | 33 | +4.59% |
| SABBY MANAGEMENT, LLC | 10 percent owner | 1192507 36.0809% | $751,279.41 | 10 | 0 | |
| DOMAIN PARTERS VII L P | 10 percent owner | 813433 24.6115% | $512,462.79 | 2 | 0 | |
| INTERWEST PARTNERS X LP | 10 percent owner | 380224 11.5042% | $239,541.12 | 2 | 0 | |
| Plovanic William J. | President & CEO | 106806 3.2316% | $67,287.78 | 3 | 0 |
*Gray background shows insiders who have made transactions during last year
RSLS Institutional Investors: Active Positions
| Increased Positions | 4 | +44.44% | 17,849 | +1,408.76% |
| Decreased Positions | 2 | -22.22% | 2 | -0.16% |
| New Positions | <1 | New | <1 | New |
| Sold Out Positions | 2 | Sold Out | 2 | Sold Out |
| Total Postitions | 11 | +22.22% | 19,114 | +1,408.6% |
RSLS Ownership Change vs Market
Institutional Investor Ownership
Top Shareholders
Top Buyers
Top Sellers
New Shareholders
Sold-Out Shareholders
Active Shareholders
| Ubs Group Ag | $11.00 | 0.59% | 17,665 | +17,664 | +1.77M% | 2024-12-31 |
| Tower Research Capital Llc (Trc) | $1.00 | 0.03% | 847 | +182 | +27.37% | 2024-12-31 |
| Blackrock, Inc. | $0 | 0.02% | 588 | 0 | 0% | 2024-12-31 |
| Bank Of America Corp /De/ | $0 | 0% | 6 | +2 | +50% | 2024-12-31 |
| Cornerstone Planning Group Llc | $0 | 0% | 3 | 0 | 0% | 2024-12-31 |
| Group One Trading Llc | $0 | 0% | 2 | 0 | 0% | 2024-12-31 |
| Morgan Stanley | $0 | 0% | 1 | 0 | 0% | 2024-12-31 |
| Sbi Securities Co., Ltd. | $0 | 0% | 1 | +<1 | New | 2024-12-31 |
| Cibc Private Wealth Group Llc | $0 | 0% | 1 | 0 | 0% | 2024-12-31 |
| Jpmorgan Chase & Co | $0 | 0% | 0 | <1 | Sold Out | 2024-12-31 |
Financial Ratios
Summary
Comparison with Competitors
Analyst Recommendations
Analyst Price Targets
No data is available at this moment.
Screener Ideas
Dividend StocksBlue Chip StocksDefensive StocksGrowth StocksValue StocksCyclical StocksPenny StocksPrismo does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. Prismo does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.